LDZU Stock Chart & Stats
€7.70
-€0.05(-0.65%)
At close: 4:00 PM EDT
€7.70
-€0.05(-0.65%)
Day’s Range― - ―
52-Week Range€4.26 - €8.40
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€3.48B
Enterprise Value€4.78K
Total Cash (Recent Filing)€5.61B
Total Debt (Recent Filing)€32.91B
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.67
Shares Outstanding446,252,320
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.63
Price to Sales (P/S)1.23
P/FCF Ratio512.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.67
Revenue Forecast (FY)€2.07B
Bulls Say, Bears Say
Bulls Say
APAC Divestment To Materially Reduce DebtA completed APAC sale that yields >ZAR25bn is a structural deleveraging event. Eliminating most net debt and recognizing a sale profit plus recurring interest savings materially improves solvency, credit headroom and strategic optionality, enabling reinvestment or buybacks once executed.
Commercial Pharma Growth And Margin ResilienceCommercial Pharma is the core cash generator: mid-single-digit revenue growth and expanding double-digit EBITDA underpin durable cash flows. Stable high margins across injectables, prescription and OTC reduce earnings volatility versus manufacturing, supporting sustained profitability if trends continue.
Improving Operational Cash GenerationRising operating cash and disciplined capex produced ~ZAR2bn FCF in the half, showing management can convert earnings to cash. Improved working-capital and cash-cost actions enhance liquidity durability, supporting debt paydown, investments, and cushioning against cyclical pressures over the medium term.
Bears Say
Manufacturing And Steriles CollapseA severe manufacturing/steriles setback from a lost mRNA contract shows concentration and execution risk in the production business. Such large contract volatility can structurally depress margins, require restructuring and capex, and delay returns; recovery targets FY27 but execution and market wins are uncertain.
Negative Profitability And Weak ReturnsSustained negative margins and sub‑par ROE/ROIC indicate the company is not earning returns above cost of capital. Without durable margin recovery or higher-return investments, shareholder value is impaired, necessitating either structural business improvement or asset reallocation to restore returns.
Elevated Leverage And Execution Risk Until Sale CompletesLeverage remains high until the APAC divestment closes. The outcome and timing are exposed to currency and regulatory uncertainty; any delay or haircut would sustain interest burden, constrain capital allocation and raise refinancing or covenant risk, limiting strategic choices in the medium term.
Aspen Pharmacare News
LDZU FAQ
What was Aspen Pharmacare’s price range in the past 12 months?
Aspen Pharmacare lowest stock price was €4.26 and its highest was €8.40 in the past 12 months.
What is Aspen Pharmacare’s market cap?
Aspen Pharmacare’s market cap is €3.48B.
When is Aspen Pharmacare’s upcoming earnings report date?
Aspen Pharmacare’s upcoming earnings report date is Sep 02, 2026 which is in 35 days.
How were Aspen Pharmacare’s earnings last quarter?
Aspen Pharmacare released its earnings results on Mar 03, 2026. The company reported €0.167 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Aspen Pharmacare overvalued?
According to Wall Street analysts Aspen Pharmacare’s price is currently Overvalued.
Does Aspen Pharmacare pay dividends?
Aspen Pharmacare does not currently pay dividends.
What is Aspen Pharmacare’s EPS estimate?
Aspen Pharmacare’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aspen Pharmacare have?
Aspen Pharmacare has 446,252,320 shares outstanding.
What happened to Aspen Pharmacare’s price movement after its last earnings report?
Aspen Pharmacare reported an EPS of €0.167 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.379%.
Which hedge fund is a major shareholder of Aspen Pharmacare?
Currently, no hedge funds are holding shares in DE:LDZU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aspen Pharmacare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.87%
12-Months-Change
Fundamentals
Return on Equity
1.23%
Trailing 12-Months
Asset Growth
6.75%
Trailing 12-Months
Company Description
Aspen Pharmacare
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands. It also manufactures active pharmaceutical ingredients, finished dose forms, and heparins, as well as steriles, oral solid doses, liquids, semi-solids, and biologicals. The company exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
LDZU Company Deck
LDZU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveys a balanced picture: strong operational cash generation, clear commercial pharma momentum (notably GLP‑1 traction), and a material APAC divestment that should materially strengthen the balance sheet and unlock shareholder value. Offsetting these positives are significant near‑term manufacturing and sterile segment setbacks (large EBITDA and revenue hits from lost contracts), a meaningful short‑term decline in group earnings, and ongoing macro/regulatory and currency risk. Management presented a defined recovery plan (cost reshaping, contract commercialization, insulin ramp, French site wins and sterile restructuring) and targets FY27 restoration of prior EBITDA levels, but execution is required to convert the improvements signaled into sustainable results.View all DE:LDZU earnings summariesTechnical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Alvotech
―